DOI: https://doi.org/10.36347/sasjm.2025.v11i05.027

Pages: 538-541

Introduction: Basal cell carcinoma (BCC) is the most common type of skin cancer. Its severity lies in the risk of involving critical facial structures, as well as the potential functional and aesthetic sequelae. Facial involvement is a risk factor for recurrence. Methods: This is a retrospective study conducted in the radiotherapy department of the Mohammed VI University Hospital in Marrakech, during the period from January 2019 to December 2023. Results: Our study included 24 patients. The average age was 65 years, with a range from 17 to 83 years. A clear male predominance was noted, with a sex ratio of 2.3. Sun exposure was the main predisposing factor, found significantly in 70% of our patients, linked to outdoor occupations. The median time between the onset of the first symptoms and the first consultation was 4 years. The macroscopic appearance was dominated by ulcerative-budding lesions in 55% of cases. Histological examination confirmed the predominance of nodular BCC (55% of cases) followed by infiltrating BCC (25% of cases). Recurrence occurred in 35% of cases. Therapeutically, the tumors were unresectable in 15% of cases, and operated on with tumor margins in 65% of cases. Radiotherapy was indicated in 25% of patients, adjuvant in 84% of cases, and exclusive in 16% of cases, at a dose ranging from 60 to 66 Gy. Palliative chemotherapy was indicated in 15% of patients. Conclusion: Surgical excision with clear margins remains the gold standard treatment for basal cell carcinoma. Radiotherapy has an important role in cases of incomplete excision, recurrent BCC, or unresectable tumors. Improving results requires prevention (sun protection, public information) and early detection of lesions.